hGH fragment is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-11-11. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
An OECD proposal to allocate multinational profits (for taxing purposes) to countries where they do business, by a formula, including to markets which multinationals sell into without a physical presence. This is hoped to eliminate the need for Digital Services Tax implemented by several countries, including France. There are exclusions and minimum thresholds, including banking and extractive industries. The proposal involves allocating only residual profit (i.e., profits above what is established through transfer pricing, thus creating a hybrid mechanism). This is essentially no change to what is currently allowed (routine profits allocated using transfer pricing + residual profits allocated through profit split). Pillar 2
More data on this classification are discoverable at the Expasy metallothionein page.Secondary structure elements have been observed in several MTs SmtA from Syneccochoccus, mammalian MT3, echinoderm SpMTA, fish Notothenia coriiceps MT, crustacean MTH, but until this moment, the content of such structures is considered to be poor in MTs, and its functional influence is not considered. Tertiary structure of MTs is also highly heterogeneous. While vertebrate, echinoderm and crustacean MTs show a bidominial structure with divalent metals as Zn(II) or Cd(II) (the protein is folded so as to bind metals in two functionally independent domains, with a metallic cluster each), yeast and prokaryotic MTs show a monodominial structure (one domain with a single metallic cluster). In yeast, the first 40 residues in the protein wrap around the metal by forming two large parallel loops separated by a deep cleft containing the metal cluster. Although no structural data is available for molluscan, nematoda and Drosophila MTs, it is commonly assumed that the former are bidominial and the latter monodominial. No conclusive data are available for Plant MTs, but two possible structures have been proposed: 1) a bidominial structure similar to that of vertebrate MTs; 2) a codominial structure, in which two Cys-rich domains interact to form a single metallic cluster. Quaternary structure has not been broadly considered for MTs.
Smith had intended to have Dupont named Governor-General, but Queen Elizabeth II would not even consider this advice. With few exceptions, the international community backed Whitehall's assertion that Gibbs was the Queen's only legitimate representative, and hence the only lawful authority in Rhodesia. In September 1968, the Appellate Division of the High Court of Rhodesia ruled that Ian Smith's administration had become the de jure government of the country, not merely the de facto one. To support his decision, Chief Justice Sir Hugh Beadle used several statements made by Hugo Grotius, who maintained that there was no way that a nation could rightly claim to be governing a particular territory – if it was waging a war against that territory. Beadle argued that due to Britain's economic war against Rhodesia, she could not (at the same point) be described as governing Rhodesia. The ruling set the precedent that despite the UDI, the incumbent Smith government "could lawfully do anything its predecessors could lawfully have done". A Salisbury commission chaired by prominent lawyer W.R. Waley was appointed to study constitutional options open to the Rhodesian authorities as of April 1968, including on the topic of majority rule, but reopening negotiations with the British on a settlement was ruled out early on. The Waley Commission found that in practical as well as legal terms, "Europeans must surrender any belief in permanent European domination", pointing out that minority rule was not permanently sustainable.
↓: reduced serum concentration or structure parameter; ↑: increased serum concentration or structure parameter; ↔: no change; TSH: Thyroid-stimulating hormone; T3: Total triiodothyronine; T4: Total thyroxine; fT4: Free thyroxine; fT3: Free triiodothyronine; rT3: Reverse triiodothyronine
Sources: en.wikipedia.org
=== Evolution === The ancestors of American black bears and Asian black bears diverged from sun bears 4.58 mya. The American black bear then split from the Asian black bear 4.08 mya. A small, primitive bear genus called protarctos (U. abstrusus) is the oldest known North American fossil member of the genus Ursus, dated to 4.95 mya. This suggests that U. abstrusus may be the direct ancestor of the American black bear, which evolved in North America. The earliest American black bear fossils, from the Early Pleistocene of Port Kennedy, Pennsylvania, greatly resemble the Asian species, though later specimens grew to sizes comparable to grizzly bears. Once described as a precursor species (Ursus vitabilis), these specimens have been synonymized with U. americanus. The American black bear lived during the same period as the giant and lesser short-faced bears (Arctodus simus and A. pristinus, respectively) and the Florida spectacled bear (Tremarctos floridanus). These tremarctine bears evolved from bears that had emigrated from Asia to the Americas 7–8 mya. The giant and lesser short-faced bears are thought to have been heavily carnivorous and the Florida spectacled bear more herbivorous, while the American black bears remained arboreal omnivores, like their Asian ancestors. From the Holocene to the present, American black bears seem to have shrunk in size, but this has been disputed because of problems with dating these fossil specimens.
== Side effects == Seltorexant is reported to be safe and well-tolerated. Side effects of seltorexant observed in clinical trials so far have included somnolence, fatigue, dizziness, headache, abdominal discomfort, and nightmares.
Breast milk supply increases in response to the baby's demand for milk and decreases when milk is allowed to remain in the breasts. When considering a possibly low milk supply, it is important to consider the difference between "perceived low milk supply" and "true low milk supply". Perceived low milk supply occurs when mothers, for a variety of reasons, believe that they are not making enough milk to feed their infant. These reasons may include fussiness, colic, preference for the bottle as opposed to the breast, long nursing duration, decreased sensation of breast fullness, and even decreased frequency of infant stools. However, in these cases, it is important to reassure the parent that infant weight gain is absolute proof of adequate milk intake. Thus, if the infant is breastfeeding exclusively and is gaining weight appropriately, then the parent can be reassured that they are producing enough milk. True low milk supply can be either primary (caused by medical conditions or anatomical issues in the mother), secondary (caused by not thoroughly and regularly removing milk from the breasts), or both. Primary causes may manifest before or during pregnancy, during labor, and even after birth. Secondary causes are far more common than primary ones. One study found that 15% of healthy first-time mothers had low milk supply 2–3 weeks after birth, with secondary causes accounting for at least two-thirds of those cases. Poor milk intake is signaled by poor infant weight gain, signs of dehydration, and hypoglycemia.
Sources: en.wikipedia.org
=== Flagship facility === UPMC Presbyterian Shadyside is UPMC's primary flagship medical entity and represents the core of UPMC's academic, teaching, trauma, specialty and research-related facilities, serving as the system's primary academic hub and Pennsylvania's largest inpatient acute care hospital. UPMC Presbyterian Shadyside includes UPMC Presbyterian hospital and the physically conjoined UPMC Eye & Ear and UPMC Montefiore hospitals as well as the UPMC Western Psychiatric Hospital that also serves as the University of Pittsburgh's Thomas Detre Hall. These facilities are all located on the western side of the University of Pittsburgh's main campus in the Oakland neighborhood of Pittsburgh. The hospitals are also physically connected to the University of Pittsburgh School of Medicine's Scaife Hall, the University of Pittsburgh School of Nursing's Victoria Hall, Falk Clinic, three of the university's biomedical science towers, and the university's Lothrop Hall dormitory, all of which are surrounded by a variety of other academic facilities. UPMC Presbyterian Shadyside also encompasses the UPMC Shadyside hospital campus which includes the University of Pittsburgh Cancer Institute in the UPMC Hillman Cancer Center which are located near the university's Centre Plaza Apartments student housing. The UPMC Shadyside facilities are located in the adjacent neighborhood of Shadyside approximately 1.5 miles (2.4 km) from the Oakland-based hospitals and are connected by regular shuttle service.
== External links == CID 16132316 from PubChem – β-endorphin CID 3081525 from PubChem – β-endorphin (1-9) CID 133304 from PubChem – β-endorphin (2-9) β-endorphin at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
=== Pharmacokinetics === Tavaborole, when prepared with a 1:1 mixture of ethyl acetate and propylene glycol, has the ability to fully penetrate through the human nail. In studies with cadaver fingernails, a 5% solution of tavaborole penetrated the nail an average of 524.7 mcg/cm2 after two weeks of daily use. Tavaborole is detectable in the blood at a level of 3.54 ng/mL after a single use of 0.2 mL of the 5% solution. Tavaborole has an elimination half-life of 28.5 hours, a maximum concentration of 5.17 ng/mL after two weeks of daily use, and takes 8 days to reach the maximum concentration.
Eating much faster than normal, perhaps in a short space of time Eating until feeling uncomfortably full Eating a large amount even when not hungry Subjective loss of control over how much or what is eaten Planning and allocating specific times for bingeing Eating alone or secretly Not being able to remember what was eaten after the binge Feelings of guilt, shame, or disgust following a food binge Body image disturbance In contrast to bulimia nervosa, binge eating episodes are not regularly followed by activities intended to compensate for the amount of food consumed, such as self-induced vomiting, laxative or enema misuse, or strenuous exercise. BED is characterized more by overeating than dietary restriction. Those with BED often have poor body image and frequently diet, but are unsuccessful due to the severity of their binge eating. Obesity is common in persons with BED, as are depression, low self-esteem, stress and boredom. Regarding cognitive abilities, individuals showing severe binge eating symptoms may experience small dysfunctions in executive functions. Those with BED are also at risk of non-alcoholic fatty liver disease, menstrual irregularities such as amenorrhea, and gastrointestinal problems such as acid reflux and heartburn.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.